Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

The First Trust Mid Cap Growth AlphaDEX ETF (FNY) made its debut on 04/19/2011, and is a smart beta exchange traded fund that provides broad exposure to the Style Box - Mid Cap Growth category of the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

Wall Street’s main indices finished in the green but with lackluster gains, with the Nasdaq rising 0.27 percent, the S&P 500 ...

Markets enter the week on edge as Q2 earnings season kicks off with heavyweight banks and global blue chips. Investors will ...

The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade) SA analyst upgrades: NVDA, MAIN, ALB, APP, QBTS, HIMS (Update) Anavex Life Sciences GAAP EPS of -$0.13 beats by $0.02 ...

SO Britain’s second-least worst prince is on manoeuvres. Prince Andrew’s nephew, Harry, has been quietly negotiating behind ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: ...

We came across a bearish thesis on Hims & Hers on FJ Research’s Substack. As of 3ʳᵈ July, Hims & Hers’s share was trading at ...

President Donald Trump will announce $70 billion in artificial intelligence and energy investments in Pennsylvania on Tuesday, as part of White House efforts to accelerate development of emerging ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...